CLA is a natural fat from meat and dairy, sold in concentrated form mainly to reduce body fat. Human studies show only a small fat reduction and a slight lean-tissue gain, easily overshadowed by diet and exercise. The more potent form can worsen blood sugar, blood fats, and liver markers, and often upsets digestion. A minor, optional tool. (Full Review)

Protocol

Standard Dose

3.0–3.4 g/day

Mixed-isomer (~50:50) safflower-derived active CLA

Timing

With meals

Improves tolerance and fat absorption

Dosing Schedule

Split doses

Across two or three meals to reduce GI side effects

Time to effect

Body Composition

8 weeks–6 months

Fat and lean-mass changes build slowly, not within days

Benefits

High: Modest reduction in body fat mass

Medium: Small increase in lean body mass; reduced oxidative stress

Low: Reduction in leptin; immune modulation

Speculative: Anti-carcinogenic potential; anti-atherosclerotic effects

Contraindications

Type 2 diabetes or significant insulin resistance

Established metabolic syndrome

Non-alcoholic fatty liver disease or other active liver disease (ALT/AST above ~2× upper limit)

Pregnancy or breastfeeding

Prior adverse liver reaction to CLA

Bariatric or lipid-clinic patients with tightly managed metabolic targets

Key Interactions

Antidiabetic medications (metformin, sulfonylureas such as glipizide, insulin)

Lipid-lowering medications (statins such as atorvastatin, ezetimibe)

Anticoagulants and antiplatelet agents (warfarin, apixaban, aspirin, clopidogrel)

Over-the-counter agents (high-dose omega-6 oils, other concentrated fatty-acid products, NSAIDs such as ibuprofen)

Supplement interactions (omega-3 fish oil, carnitine, green-tea extract)

Additive metabolic-risk agents (high-dose niacin)

Risk & Side Effects

High: Worsened insulin sensitivity & glycemic control; gastrointestinal discomfort

Medium: Adverse blood lipid changes; elevated liver enzymes & hepatic fat; increased systemic inflammation

Low: Increased lipid peroxidation

Speculative: Rare hepatotoxicity; prothrombotic / platelet activation potential

Monitoring

Marker	Target	Why
Fasting blood glucose	75–90 mg/dL	Detects CLA's tendency to raise glucose
Fasting insulin / HOMA-IR	Insulin < 6 µIU/mL; HOMA-IR < 1.5	Tracks insulin sensitivity, CLA's key metabolic risk
Hemoglobin A1c	< 5.4%	Confirms longer-term glucose control
Triglycerides	< 80 mg/dL	Flags CLA-related rises in blood fats
HDL cholesterol	> 55 mg/dL	Monitors the "good" cholesterol CLA may modestly raise
LDL cholesterol	< 100 mg/dL	Detects unfavorable LDL increases
ALT and AST	< 25 U/L (women), < 30 U/L (men)	Detects liver-enzyme elevation and possible liver-fat shift
GGT	< 20 U/L	Sensitive early marker of liver stress
High-sensitivity CRP	< 1.0 mg/L	Screens for inflammatory shifts

Cadence: Baseline, 8–12 weeks, then every 3–6 months if use continues

Qualitative Assessment

Digestive comfort (absence of persistent nausea, loose stools, or abdominal discomfort)
Perceived changes in body composition (waist fit, muscle definition) rather than scale weight alone
Energy levels and exercise performance
Appetite and satiety

CLA for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment